In this issue:
Adherence, persistence, and switching with ixekizumab and secukinumab
Work/study productivity with guselkumab in moderate-to-severe psoriasis
Ixekizumab for moderate-to-severe plaque psoriasis
Risk of hepatitis B virus reactivation with biological agents
Cumulative clinical benefits of biologics for moderate-to-severe psoriasis
Biologic therapy for ≥10 years for moderate-to-severe psoriasis
Management of oral candidiasis in IL recipients
Ixekizumab in Japanese generalised pustular psoriasis and erythrodermic psoriasis patients
Impact of methotrexate and adalimumab on immune function
Guselkumab outcomes in patients with plaque psoriasis
Please login below to download this issue (PDF)